Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Class I drug recalls - the high-risk category

Class I is the FDA's most serious recall category: a reasonable probability that using the product will cause serious health consequences or death. It is a small share of all recalls, but the one to check first if a medication you take appears here.

1,750 recalls, newest first.

Class I · High risk

Adrenalin Chloride Solution

Labeling: Not Elsewhere Classified: misleading label similar in appearance to the FDA-approved drug product Adrenalin¿ (epinephrine injection, USP)

Ongoing Labeling / mix-up ENDO USA, Inc. NDC 42023-103-01 D-0223-2025
Class I · High risk

Clonazepam Orally Disintegrating Tablets

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.

Ongoing Labeling / mix-up Endo USA, Inc. D-0181-2025
Class I · High risk

Clonazepam Orally Disintegrating Tablets

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.

Ongoing Labeling / mix-up Endo USA, Inc. D-0180-2025
Class I · High risk

Clonazepam Orally Disintegrating Tablets

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.

Ongoing Labeling / mix-up Endo USA, Inc. D-0179-2025
Class I · High risk

Clonazepam Orally Disintegrating Tablet

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.

Ongoing Labeling / mix-up Endo USA, Inc. D-0178-2025
Class I · High risk

ZapMax Capsules

Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.

Ongoing Chemical / undeclared Boulla LLC D-0086-2025
Class I · High risk

ZoomMax Capsules

Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.

Ongoing Chemical / undeclared Boulla LLC D-0085-2025
Class I · High risk

PeakMax Capsules

Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.

Ongoing Chemical / undeclared Boulla LLC D-0084-2025
Class I · High risk

VitalityXtra Capsules

Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and diclofenac.

Ongoing Chemical / undeclared Boulla LLC D-0083-2025
Class I · High risk

Atovaquone Oral Suspension

Microbial Contamination of a Non-sterile Product: The product was found to be contaminated with Cohnella bacteria.

Terminated Microbial contamination Bionpharma Inc. NDC 69452-252-87 D-0012-2025
Class I · High risk

Umary Acido Hialuronico

Marketed without Approved NDA/ANDA. FDA analysis found product to be tainted with undeclared Diclofenac and Omeprazole.

Ongoing Chemical / undeclared Main Products INC D-0626-2024
Class I · High risk

Umary Acido Hialuronico

Marketed without an Approved NDA/ANDA: FDA analysis found product to be tainted with undeclared Diclofenac and Omeprazole.

Ongoing Chemical / undeclared SoloVital D-0620-2024
Class I · High risk

Gold Hard Steel Plus Liquid

Marketed without an approved NDA/ANDA: FDA analysis found products to be tainted with undeclared acetaminophen and sildenafil.

Ongoing Chemical / undeclared Supercore Products Group Inc. D-0004-2025
Class I · High risk

Healthy Living Acetaminophen

Labeling: Missing Label - some bottles are missing the the manufacturers label that includes the drug facts information.

Ongoing Labeling / mix-up Aurobindo Pharma USA Inc NDC 58602-882-21 D-0641-2024
Class I · High risk

Clonazepam Orally Disintegrating Tablets

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled as 0.125 mg instead of 0.25 mg. The blister strips inside the product carton reflect the correct strength of 0.25 mg.

Terminated Labeling / mix-up Endo Pharmaceuticals, Inc. NDC 49884-306-02 D-0622-2024

Recalls by year